Literature DB >> 21195801

High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.

Jiangmei Yin1, Anlan Dai, Jonathan Lecureux, Tatiana Arango, Michele A Kutzler, Jian Yan, Mark G Lewis, Amir Khan, Niranjan Y Sardesai, David Montefiore, Ruth Ruprecht, David B Weiner, Jean D Boyer.   

Abstract

BACKGROUND: Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China and there is a critical need for a vaccine targeted to these areas. In this study we tested a DNA based vaccine that encodes the SIVgag, SIVpol and HIV-1 envelope clade C.
METHODS: Rhesus macaques were immunized by electroporation with the DNA plasmid encoding optimized SIVgag, SIVpol and an HIV-1 env clade C with or without the adjuvant RANTES. Animals were monitored for immune responses and challenged following the final immunization with 25 animal infectious doses (AID) of SHIV-1157ipd3N4.
RESULTS: We found that the vaccine induced high levels of antigen specific IFN-γ producing effector cells and the capacity for CD4+ and CD8+ to proliferate upon antigen stimulation. Importantly, we found that the vaccine induced antibody titers as high as 1/4000. These antibodies were capable of neutralizing tier 1 HIV-1 viruses. Finally, when macaques were challenged with SHIV, viral loads were controlled in vaccinated groups.
CONCLUSION: We conclude that immunization with a simian/human immunodeficiency virus DNA-based vaccine delivered by electroporation can induce cellular and humoral immune responses that are able to control viral replication.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195801     DOI: 10.1016/j.vaccine.2010.12.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.

Authors:  Natalie A Hutnick; Devin J F Myles; Bernadette Ferraro; Colleen Lucke; Feng Lin; Jian Yan; Kate E Broderick; Amir S Khan; Niranjian Y Sardesai; David B Weiner
Journal:  Hum Gene Ther       Date:  2012-08-02       Impact factor: 5.695

2.  Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.

Authors:  Viraj Kulkarni; Margherita Rosati; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Cristina Bergamaschi; Ashish K Singh; Candido Alicea; Bhabadeb Chowdhury; Gen-Mu Zhang; Eun-Young Kim; Steven M Wolinsky; Wensheng Huang; Yongjun Guan; Celia LaBranche; David C Montefiori; Kate E Broderick; Niranjan Y Sardesai; Antonio Valentin; Barbara K Felber; George N Pavlakis
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

Review 3.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

4.  IL-4 and IFN-γ induced by human immunodeficiency virus vaccine in a schistosome infection model.

Authors:  Jiangmei Yin; Anlan Dai; Tatiana Arango; Ravi S Kasinathan; Robert M Greenberg; Jean D Boyer
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

5.  Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Authors:  Jamie F S Mann; Paul F McKay; Anezka Fiserova; Katja Klein; Alethea Cope; Paul Rogers; Julie Swales; Michael S Seaman; Behazine Combadiere; Robin J Shattock
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Authors:  Jinyao Li; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Rachel Kelly Beach; Candido Alicea; Drew Hannaman; Steven G Reed; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2013-04-26       Impact factor: 3.641

7.  Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.

Authors:  Viraj Kulkarni; Margherita Rosati; Antonio Valentin; Rashmi Jalah; Candido Alicea; Lei Yu; Yongjun Guan; Xiaoying Shen; Georgia D Tomaras; Celia LaBranche; David C Montefiori; Carmela Irene; Rajasekhar Prattipati; Abraham Pinter; Sean M Sullivan; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2013-07-02       Impact factor: 3.452

8.  Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Authors:  Josephine H Cox; Maria G Ferrari; Patricia Earl; James R Lane; Linda L Jagodzinski; Victoria R Polonis; Ellen G Kuta; Jean D Boyer; Silvia Ratto-Kim; Leigh-Anne Eller; Doan-Trang Pham; Lydia Hart; David Montefiori; Guido Ferrari; Stephanie Parrish; David B Weiner; Bernard Moss; Jerome H Kim; Deborah Birx; Thomas C VanCott
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

9.  Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Authors:  Peter Hayes; Jill Gilmour; Andrea von Lieven; Dilbinder Gill; Lorna Clark; Jakub Kopycinski; Hannah Cheeseman; Amy Chung; Galit Alter; Len Dally; Devika Zachariah; Angela Lombardo; James Ackland; Eddy Sayeed; Akil Jackson; Marta Boffito; Brian Gazzard; Patricia E Fast; Josephine H Cox; Dagna Laufer
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

10.  Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.

Authors:  Huihui Bao; Aarti A Ramanathan; Omkar Kawalakar; Senthil G Sundaram; Colleen Tingey; Charoran B Bian; Nagarajan Muruganandam; Paluru Vijayachari; Niranjan Y Sardesai; David B Weiner; Kenneth E Ugen; Karuppiah Muthumani
Journal:  Viral Immunol       Date:  2013-02       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.